Geriatric Nutritional Risk Index and Newly Developed Scoring System As Prognosis Prediction for Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib

In the current era of immune therapy, lenvatinib (LEN) continues to be vital for treating unresectable hepatocellular carcinoma (uHCC) patients. This study investigates the importance of nutritional status in the prognosis of uHCC patients receiving LEN and evaluates a new prognostic scoring system that combines the geriatric nutritional risk index (GNRI) and systemic inflammatory response. From 2018 to 2022, 484 uHCC patients treated with LEN (384 males, median age 73). Prognostic value was compared between GNRI and C-reactive protein (CRP) scoring (GNRI-C score), GNRI, and neo-Glasgow prognostic score (neo-GPS). Evaluation was based on the Akaike information criterion (AIC) and concordance index(c-index). Median progression-free survival (mPFS) was 9.3/6.8/4.6 months for GNRI no-risk/low-risk/moderate-to-major risk (p < 0.01, AIC 4742.4/c-index 0.585). Median overall survival (mOS) was 27.8/15.2/9.5 months (p < 0.01, AIC 3433.34/c-index 0.639). For GNRI-C score, mPFS was 10.8/7.1/5.6/4.0 months (score 0/1/2/3) (p < 0.01, AIC 4732.82/c-index 0.6), while neo-GPS showed mPFS of 8.5/5.1/5.2 months (p < 0.01, AIC 4745.89/c-index 0.562). For mOS, GNRI-C score demonstrated 28.6/20.0/10.1/8.4 months (score 0/1/2/3) (p < 0.01, AIC 3420.27/c-index 0.652), while neo-GPS indicated 21.0/12.4/4.5 months (p < 0.01, AIC 3468.84/c-index 0.564). The newly devised GNRI-C score, incorporating nutritional and inflammatory markers, could offer improved prognostic predictions for uHCC patients treated with LEN.

References

Sasaki M, Miyoshi N, Fujino S, Ogino T, Takahashi H, Uemura M . The Geriatric Nutritional Risk Index predicts postoperative complications and prognosis in elderly patients with colorectal cancer after curative surgery. Sci Rep. 2020; 10(1):10744. PMC: 7329855. DOI: 10.1038/s41598-020-67285-y. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E . Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med. 2018; 8(1):137-146. PMC: 6346240. DOI: 10.1002/cam4.1909. View

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

Vellas B, Guigoz Y, Garry P, Nourhashemi F, Bennahum D, Lauque S . The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition. 1999; 15(2):116-22. DOI: 10.1016/s0899-9007(98)00171-3. View

Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H . Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2015; 31(5):1031-6. DOI: 10.1111/jgh.13250. View

Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T . Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2016; 52(4):512-519. PMC: 5357473. DOI: 10.1007/s00535-016-1263-4. View

Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J . Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. Eur J Gastroenterol Hepatol. 2022; 34(8):857-864. DOI: 10.1097/MEG.0000000000002398. View

Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M . Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Liver Int. 2020; 40(4):968-976. DOI: 10.1111/liv.14405. View

10.

Kanno H, Goto Y, Sasaki S, Fukutomi S, Hisaka T, Fujita F . Geriatric nutritional risk index predicts prognosis in hepatocellular carcinoma after hepatectomy: a propensity score matching analysis. Sci Rep. 2021; 11(1):9038. PMC: 8079680. DOI: 10.1038/s41598-021-88254-z. View

11.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

12.

Zhu A, Kang Y, Yen C, Finn R, Galle P, Llovet J . Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2):282-296. DOI: 10.1016/S1470-2045(18)30937-9. View

13.

Sonehara K, Tateishi K, Araki T, Komatsu M, Yamamoto H, Hanaoka M . Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced non-small cell lung cancer who subsequently underwent immunotherapy. Thorac Cancer. 2021; 12(9):1366-1372. PMC: 8088948. DOI: 10.1111/1759-7714.13909. View

14.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

15.

Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent J, Nicolis I . Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005; 82(4):777-83. DOI: 10.1093/ajcn/82.4.777. View

16.

Morris-Stiff G, Gomez D, Prasad K . C-reactive protein in liver cancer surgery. Eur J Surg Oncol. 2008; 34(7):727-9. DOI: 10.1016/j.ejso.2008.01.016. View

17.

Abou-Alfa G, Meyer T, Cheng A, El-Khoueiry A, Rimassa L, Ryoo B . Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379(1):54-63. PMC: 7523244. DOI: 10.1056/NEJMoa1717002. View

18.

Hiraoka A, Kumada T, Kariyama K, Tada T, Tani J, Fukunishi S . Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. J Gastroenterol Hepatol. 2020; 36(7):1812-1819. PMC: 8359359. DOI: 10.1111/jgh.15336. View

19.

Si Y, Xu P, Xu A, Wang P, Zhao K . Geriatric nutritional risk index as a prognostic factor in patients with hepatocellular carcinoma following transarterial chemoembolization: A retrospective study. Medicine (Baltimore). 2023; 101(51):e32322. PMC: 9794247. DOI: 10.1097/MD.0000000000032322. View

20.

Gomes-Neto A, van Vliet I, Oste M, de Jong M, Bakker S, Jager-Wittenaar H . Malnutrition Universal Screening Tool and Patient-Generated Subjective Global Assessment Short Form and their predictive validity in hospitalized patients. Clin Nutr ESPEN. 2021; 45:252-261. DOI: 10.1016/j.clnesp.2021.08.015. View